Market Overview

Vetr Upgrades Valeant After Price Dips

Related VRX
Benzinga's Bulls & Bears Of The Week: Amazon, Costco, Netflix, Tesla And More
Dear Activists: Buying Stock Can Effect More Change Than Selling It
Valeant: A Rifamycin Threat Could Be Devastating (Seeking Alpha)

The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade was largely positive, with 80 percent of Vetr user ratings bullish.

Share price In Valeant is back on the uptrend after dipping below $17 earlier in the week after hitting a four-month high of $17.75. The stock closed Thursday's session up, but still below that high at $17.65

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Valeant is up at $22.46, which is still below the average analyst price target of $24.58. Valeant Pharmaceuticals is a popular stock on Vetr as more than 2 percent of users are holding VRX in their watch-lists.

Latest Ratings for VRX

Mar 2018Deutsche BankUpgradesHoldBuy
Jan 2018Goldman SachsInitiates Coverage OnSell
Dec 2017JP MorganDowngradesNeutralUnderweight

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General


Related Articles (VRX)

View Comments and Join the Discussion!